ABSTRACT
We evaluated two commercial human T-cell lymphotropic virus (HTLV) Western blot (WB; immunoblot) kits, Cambridge Biotech Corp. (CBC) and Diagnostic Biotechnology Ltd. (DBL). Both methods employ HTLV type I (HTLV-I) viral lysate and rgp21. The DBL WB kit also distinguishes between HTLV-I and HTLV-II antibodies, using an HTLV-I-specific and an HTLV-II-specific recombinant. Fifty weakly reactive HTLV-II-positive plasma specimens which were falsely negative with the Abbott enzyme immunoassay (EIA) and 50 Ortho EIA false-positive samples were selected to determine sensitivity and specificity. The sensitivities of the CBC and the DBL WB kits were 90 and 68%, respectively. All positive samples reacted with rgp21 in both kits, but some did not display core bands. Five samples were typed as HTLV-I and four were typed as dual infection by the DBL WB kit. The specificities of the CBC and DBL kits were 48 and 70%, respectively. The most prevalent WB reaction with the negative samples was with the core protein, p19, followed by p24 and p28 for CBC and rgp21 and p28 for DBL. DBL had two false-positive interpretations, and CBC had none, rgp21 was the most sensitive antigen in both kits for the weakly reactive HTLV-II samples. If all samples not reacting with this protein were interpreted as WB negative, regardless of other bands, the specificity would improve to 90% for CBC and 86% for DBL.
Subject(s)
Blotting, Western , Deltaretrovirus Antibodies/blood , Gene Products, env/immunology , Human T-lymphotropic virus 1/immunology , Human T-lymphotropic virus 2/immunology , Reagent Kits, Diagnostic , Retroviridae Proteins, Oncogenic/immunology , Deltaretrovirus Antibodies/immunology , Evaluation Studies as Topic , False Negative Reactions , False Positive Reactions , Humans , Polymerase Chain Reaction , Sensitivity and Specificity , env Gene Products, Human Immunodeficiency VirusABSTRACT
Twenty human T-lymphotropic virus type I (HTLV-I) antibody-positive sera from Japan, Hawaii, and the Marshall Islands and 15 HTLV type II (HTLV-II) antibody-positive sera from intravenous drug users in the United States were tested by immunoblotting with two recombinant HTLV-I proteins and three commercial kits to determine whether there were any differences in reactions between HTLV-I- and HTLV-II-positive sera by the Western immunoblot method and, also, to evaluate the ability of these reagents to detect HTLV-I- and HTLV-II-seropositive individuals by using the recommended Western blot interpretation. These sera were first extensively characterized by immunofluorescence, enzyme immunoassay, radioimmunoprecipitation assay, and Western blot using HTLV-I and HTLV-II viral lysates and an envelope (env) recombinant protein. Although both HTLV-I- and HTLV-II antibody-positive sera reacted with the env protein gp68, reactions with the gp46 env antigens appeared to be specific for HTLV-I. It was found that the use of either p19 or p24 core bands plus an env reaction instead of only the p24 plus env reaction (as presently recommended) increased the number of positive interpretations for HTLV-I but had no effect on the number of HTLV-II-positive interpretations.
Subject(s)
Blotting, Western/methods , Deltaretrovirus Antigens , Gene Products, env , HTLV-I Antibodies/blood , HTLV-II Antibodies/blood , Evaluation Studies as Topic , Fluorescent Antibody Technique , Humans , Immunoenzyme Techniques , Indicators and Reagents , Radioimmunoprecipitation Assay , Recombinant Proteins/immunology , Retroviridae Proteins, Oncogenic/immunology , Viral Envelope Proteins/immunologyABSTRACT
Five hundred forty-eight uncoagulated blood specimens from intravenous drug users infected with human T-lymphotropic virus type II (HTLV-II) were used to evaluate the sensitivities of the radioimmunoprecipitation assay (RIPA) and PCR for detecting HTLV-II-infected people. The sensitivities of both RIPA and PCR were found to be dependent on the HTLV-II antibody titer, as determined by the immunofluorescence assay. Neither of these recommended confirmatory methods was as sensitive for detecting weakly reactive HTLV-II specimens as the immunofluorescence assay, Western blotting (immunoblotting), or a modified licensed enzyme immunoassay. Use of RIPA and PCR to determine the reliabilities of other tests may sometimes give erroneous results.
Subject(s)
HTLV-II Infections/diagnosis , Polymerase Chain Reaction , Radioimmunoprecipitation Assay , DNA, Viral/analysis , HTLV-II Antibodies/blood , Human T-lymphotropic virus 2/genetics , Humans , Sensitivity and SpecificityABSTRACT
A total of 3,349 serum samples were screened by the immunofluorescence (IF) method for antibody to human T-cell leukemia virus type I (HTLV-I). Only 9 of 2,409 specimens from selected individuals, blood bank donors, patients with encephalitis-meningitis, and human immunodeficiency virus antibody-positive homosexual or bisexual men were reactive by IF. In addition, 940 serum samples from intravenous drug abusers were tested by IF and also by an HTLV-I enzyme immunoassay (EIA) method. Of these, 222 (24%) were positive for both HTLV-I and HTLV-II antigens by IF, and 191 of these 222 were also reactive in the HTLV-I EIA. Of the 31 IF-positive, EIA-negative serum samples, 20 exhibited optical density readings greater than or equal to 70% of the positive cutoff in the EIA, and 29 samples reacted with 1 or more bands in the Western blot (immunoblot) test. An additional 10 specimens that were EIA negative reacted only with HTLV-I by IF. Differences in staining morphology and in reactions on HTLV-I and HTLV-II antigens before and after absorption of the serum specimens with HTLV-I and HTLV-II-infected cell pellets revealed six distinct serological patterns by IF. These results indicate that infections by HTLV-I or by another closely related retrovirus(es) occur in California. Further studies utilizing statistically valid sampling methods are needed to estimate true prevalence rates among various groups. IF and Western blot tests should supplement the EIA method to maximize sensitivity and specificity of test procedures.
Subject(s)
HTLV-I Antibodies/analysis , Blotting, Western , Fluorescent Antibody Technique , Humans , Immunoenzyme Techniques , Predictive Value of TestsABSTRACT
There was 100% agreement between enzyme immunoassay (EIA) (Abbott Laboratories), Western blot, and indirect immunofluorescence (IF) when these three methods were used to measure antibody to the acquired immune deficiency syndrome (AIDS) virus in sera from 142 high-risk individuals, indicating that IF was a sensitive alternative method for detecting antibody to this agent. Thirty-two (64%) of 50 EIA-positive plasma specimens from a blood bank and 6 (21%) of 28 EIA-positive sera from alternative testing sites were negative by IF. In addition, two EIA-negative sera from the latter group were positive by IF. Western blotting agreed with IF on those 40 specimens which gave discrepant results by EIA and IF. The IF method was determined to be equal to Western blotting in sensitivity and specificity for detection of AIDS antibody, and it was found to be useful for confirming positive EIA results, especially in specimens from individuals in low-risk groups.